"The capability to accurately detect structural variants is transformative for clinical diagnostics," said Adrienne Flanagan, Professor at UCL and Consultant Histopathologist at RNOH. "SAVANA could help us confidently identify genomic alterations relevant for diagnosis and prognosis. Ultimately, this means we would be better placed to deliver personalised treatments for cancer patients."
UK Investment in Clinical Genomics
The development of SAVANA comes at a pivotal moment for the United Kingdom’s healthcare infrastructure. The UK is currently making substantial investments in genomic sequencing through the NHS Genomic Medicine Service. This initiative is a global pioneer, being the first of its kind to offer whole-genome sequencing as a routine part of patient care. By embedding these advanced technologies into the everyday workflow of the National Health Service, the UK aims to drastically improve diagnostic accuracy and provide a foundation for personalized medicine.
However, the success of this massive investment hinges on the ability to interpret the data. Without specialized analytical tools like SAVANA, the vast amounts of data generated by the NHS could become a bottleneck rather than a breakthrough. Genomics England has been exploring SAVANA’s integration as part of its broader mission to evaluate the clinical potential of long-read sequencing to support earlier and faster cancer diagnoses.
Greg Elgar, Director of Sequencing R&D at Genomics England, highlighted the importance of reliability in this transition. "Using SAVANA will ensure clinicians receive accurate and reliable genomic data, enabling them to confidently integrate advanced genomic sequencing methods such as long-read sequencing into routine patient care," he stated.
Expanding the Reach of Genomic Research
The impact of SAVANA is already extending into specialized nationwide and international initiatives. It is being deployed as a core component of the UK Stratified Medicine Paediatrics project. Co-led by Cortes-Ciriano and funded by Cancer Research UK and Children With Cancer UK, this project aims to develop more effective and less toxic treatments for childhood cancers. By using SAVANA to better understand tumor biology and monitor disease recurrence in children, researchers hope to move away from "one-size-fits-all" chemotherapy and toward targeted interventions.
Beyond the UK, SAVANA is playing a role in addressing global health inequities through the Societal, Ancestry, Molecular and Biological Analyses of Inequalities (SAMBAI) project. This Cancer Grand Challenges initiative is focused on understanding and addressing cancer disparities in populations of recent African heritage. By providing a more accurate tool for genomic analysis, SAVANA helps ensure that the benefits of the genomic revolution are accessible to diverse populations, regardless of their ancestral background.
As long-read sequencing continues to move toward the center of oncology, tools like SAVANA represent the vital link between raw biological data and actionable medical insights. By providing a clearer, more accurate map of the cancer genome, this new algorithm is helping to pave the way for a future where every patient’s treatment is as unique as their own genetic code.
